Collectively, this data indicates that AXL can signal through HER3 via NRG1 to promote cetuximab resistance and that targeting of NRG1 could have significant clinical implications for HNSCC therapeutic approaches. This evidence concerns the gene NRG1 and head and neck squamous cell carcinoma.